Cargando…
Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature
BACKGROUND: Pulmonary carcinoids (PC), including typical (TC) and atypical carcinoids (AC), are low-grade neuroendocrine tumors (NETs) which account for 1–5% of all lung tumors. Due to the low prevalence of PC and extreme rarity of anaplastic lymphoma kinase (ALK) rearrangements in patients with PC,...
Autores principales: | Lei, Xi, Zhu, Shuai, Ren, Dian, Ren, Fan, Li, Tong, Zhou, Ning, Li, Shuo, Shi, Tao, Zu, Lingling, Song, Zuoqing, Chalubinska-Fendler, Justyna, Denis, Marc G., Bernicker, Eric H., Thomas de Montpréville, Vincent, Jiang, Richeng, Xu, Song |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271430/ https://www.ncbi.nlm.nih.gov/pubmed/35832448 http://dx.doi.org/10.21037/tlcr-22-394 |
Ejemplares similares
-
Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: a case report
por: Zhai, Xiaoqian, et al.
Publicado: (2022) -
High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report
por: Li, Yan, et al.
Publicado: (2022) -
Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report
por: Gu, Xiaodong, et al.
Publicado: (2022) -
Hybrid video-assisted thoracoscopic surgery sleeve lobectomy for non-small cell lung cancer: a case report
por: Zhang, Chenlei, et al.
Publicado: (2020) -
First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up
por: Jia, Ziqi, et al.
Publicado: (2020)